References
- Yang F, Long N, Anekpuritanang T, et al. Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML. Blood. 2022;139(8):1208–1221.
- Feurstein SK, Trottier AM, Estrada-Merly N, et al. Germline predisposition variants occur in myelodysplastic syndrome patients of all ages. Blood. 2022;140(24):2533–2548.
- Ahmadmehrabi K, Haque AR, Aleem A, et al. Targeted therapies for the evolving molecular landscape of acute myeloid leukemia. Cancers. 2021;13(18):4646.
- Roloff GW, Drazer MW, Godley LA. Inherited susceptibility to hematopoietic malignancies in the era of precision oncology. J Clin Oncol Precision Oncology. 2021;5:107–122
- Roloff GW, Shaw R, O’Connor TE, Hathaway F, Drazer MW. Stagnation in quality of next-generation sequencing assays for the diagnosis of hereditary hematopoietic malignancies. J Genet Couns, 2023;(00):1– 6.
- Roloff GW, Godley LA, Drazer MW. Assessment of technical heterogeneity among diagnostic tests to detect germline risk variants for hematopoietic malignancies. Genet Med. 2020; 23(1):211-214.
- Amendola LM, Hart MR, Bennett RL, et al. Insurance coverage does not predict outcomes of genetic testing: the search for meaning in payer decisions for germline cancer tests. J Genet Couns. 2019;28(6):1208–1213.
- Network N. NCCN clinical practice guidelines in oncology (NCCN guidelines): myelodysplastic syndromes version 1.2023; 2022.
- Fenaux P, Haase D, Santini V, et al. Myelodysplastic syndromes: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(2):142–156.
- Killick SB, Wiseman DH, Quek L, et al. British society for haematology guidelines for the diagnosis and evaluation of prognosis of adult myelodysplastic syndromes. Br J Haematol. 2021;194(2):282–293.
- Speight B, Hanson H, Turnbull C, et al. Germline predisposition to haematological malignancies: best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group. Br J Haematol. 2023;201(1):25–34.
- Clark A, Thomas S, Hamblin A, et al. Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar, NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group and the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT. Br J Haematol. 2023;201(1):35–44.
- Network N. NCCN clinical practice guidelines in oncology (NCCN guidelines) Acute myeloid leukemia version 3.2023; 2023.
- Heuser M, Ofran Y, Boissel N, et al. Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(6):697–712.
- de Haas V, Ismaila N, Advani A, et al. Initial diagnostic work-up of acute leukemia: ASCO clinical practice guideline endorsement of the college of American pathologists and American Society of Hematology Guideline. J Clin Oncol. 2019;37(3):239–253.
- Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–1377.
- Baliakas P, Tesi B, Wartiovaara-Kautto U, et al. Nordic guidelines for germline predisposition to myeloid neoplasms in adults: recommendations for genetic diagnosis, clinical management and follow-up. Hemasphere. 2019;3(6):e321.